Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients

• Үндсэн зохиолчид: Huanhuan Wang (Зохиогч), Xiaoyun Hu (Зохиогч), Teng Wang (Зохиогч), Cheng Cui (Зохиогч), Ji Jiang (Зохиогч), Kai Dong (Зохиогч), Shuai Chen (Зохиогч), Chunyan Jin (Зохиогч), Qian Zhao (Зохиогч), Bin Du (Зохиогч), Pei Hu (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2021-04-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study was to optimize dosing selection for a Phase IIb clinical trial using an exposure-response model.Methods: Data of 34 sepsis patients from a Phase IIa...